Literature DB >> 29564917

Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats.

Maha Mohamed Sabry1, Manal Moustafa Mahmoud1, Heba Samy Shoukry1, Laila Rashed2, Samaa Samir Kamar3, Mona Mohamed Ahmed1.   

Abstract

Apelin and its receptor (APJ) are involved in the regulation of a variety of pathophysiological processes. We studied the effect of apelin treatment on obesity-induced type 2 diabetes mellitus (T2DM) and possible interaction between apelin/APJ system and renin-angiotensin system (RAS). Forty eight male albino rats were divided into two groups: control group and diabetic group. Diabetic group was subdivided into: control diabetic, apelin-treated, apelin + losartan-treated, apelin + l-NAME-treated and losartan-treated diabetic subgroup. Administration of apelin-13 yielded an improvement of IR, dyslipidaemia, inflammation, oxidative stress with significant decrease in AT1R gene expression and significant increase in ACE2 gene expression in adipose tissues. Losartan + apelin yielded a further significant decrease in ATR1 gene expression, glycaemic indices, serum TGs and TPA versus Apelin only. Adding l-NAME in subgroup (2D) reversed the effect of apelin. We suggested that the beneficial effect of Apelin is mainly mediated by NO-activated pathway and/or ACE2/Ang (1-7) dependent pathway.

Entities:  

Keywords:  Type 2 diabetes mellitus (T2DM); apelin; endothelial nitric oxide synthase (eNOS); renin–angiotensin system (RAS)

Mesh:

Substances:

Year:  2018        PMID: 29564917     DOI: 10.1080/13813455.2018.1453521

Source DB:  PubMed          Journal:  Arch Physiol Biochem        ISSN: 1381-3455            Impact factor:   4.076


  8 in total

1.  Apelin-potential therapy for COVID-19?

Authors:  Seyed Soheil Saeedi Saravi; Jürg H Beer
Journal:  J Mol Cell Cardiol       Date:  2020-06-17       Impact factor: 5.000

Review 2.  Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.

Authors:  Murat Oz; Dietrich Ernst Lorke
Journal:  Biomed Pharmacother       Date:  2021-01-05       Impact factor: 6.529

3.  Apelin protects against ischemia-reperfusion injury in diabetic myocardium via inhibiting apoptosis and oxidative stress through PI3K and p38-MAPK signaling pathways.

Authors:  Songtao An; Xi Wang; Huairui Shi; Xueqiang Zhang; Hua Meng; Wenbo Li; Dongchang Chen; Junbo Ge
Journal:  Aging (Albany NY)       Date:  2020-12-20       Impact factor: 5.682

4.  Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies.

Authors:  Hisashi Kai; Mamiko Kai; Hiroshi Niiyama; Norihito Okina; Motoki Sasaki; Takanobu Maeda; Atsushi Katoh
Journal:  Hypertens Res       Date:  2021-03-10       Impact factor: 3.872

Review 5.  Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: An Update.

Authors:  Ethan S Palmer; Nigel Irwin; Finbarr Pm O'Harte
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2022-02-11

Review 6.  The role of Elabela in kidney disease.

Authors:  Qian Zheng; Geng Tian; Feng Xu; Xin Ci; Rumei Luan; Linlin Wu; Xuehong Lu
Journal:  Int Urol Nephrol       Date:  2021-03-08       Impact factor: 2.370

7.  Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.

Authors:  Hajira Dambha-Miller; Ali Albasri; Sam Hodgson; Christopher R Wilcox; Shareen Khan; Nazrul Islam; Paul Little; Simon J Griffin
Journal:  BMJ Open       Date:  2020-09-14       Impact factor: 2.692

8.  Apelin‑13 alleviates diabetic nephropathy by enhancing nitric oxide production and suppressing kidney tissue fibrosis.

Authors:  Zhuo Gao; Xin Zhong; Ying-Xia Tan; Dong Liu
Journal:  Int J Mol Med       Date:  2021-07-19       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.